Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P G Ambrose

Showing results (1-10 of 41) with videos related to

Pageof 5
Sort By:
The Pediatric Infectious Disease Journal|August 26, 2000
Limitations of single point pharmacodynamic analysisP G Ambrose, R Quintiliani
The Medical Clinics of North America|January 13, 2001
Clinical use of the fluoroquinolonesR C Owens, P G Ambrose
Seminars in Respiratory and Critical Care Medicine|August 10, 2005
New antibiotics in pulmonary and critical care medicine: focus on advanced generation quinolones and cephalosporinsP G Ambrose, R C Owens
Current Opinion in Microbiology|October 26, 2000
Pharmacodynamics in the study of drug resistance and establishing in vitro susceptibility breakpoints: ready for prime timeM N Dudley, P G Ambrose
Diagnostic Microbiology and Infectious Disease|December 8, 2000
The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs: fluoroquinolone pharmacodynamics against Streptococcus pneumoniaeP G Ambrose, D M Grasela
The American Journal of Medicine|January 5, 2002
Pharmacodynamic profiling of levofloxacin and gatifloxacin using Monte Carlo simulation for community-acquired isolates of Streptococcus pneumoniaeD P Nicolau, P G Ambrose
Infection|July 25, 2009
A long journey from minimum inhibitory concentration testing to clinically predictive breakpoints: deterministic and probabilistic approaches in deriving breakpointsA Dalhoff, P G Ambrose, J W Mouton
The Medical Clinics of North America|January 13, 2001
Antimicrobial pharmacodynamicsP G Ambrose, R C Owens, D Grasela
The Annals of Pharmacotherapy|May 1, 1997
Pharmacoeconomic analysis of administration of famotidine i.v. push vs.intermittent slow i.v. infusionP G Ambrose, R Quintiliani, C H Nightingale
Connecticut Medicine|April 1, 1997
Ceftazidime to cefepime formulary switch: pharmacodynamic and pharmacoeconomic rationaleR C Owens, P G Ambrose, R Quintiliani
Pageof 5

Showing results (1-10 of 41) with videos related to

Sort By:
Pageof 5
The Pediatric Infectious Disease Journal|August 26, 2000
Limitations of single point pharmacodynamic analysisP G Ambrose, R Quintiliani
The Medical Clinics of North America|January 13, 2001
Clinical use of the fluoroquinolonesR C Owens, P G Ambrose
Seminars in Respiratory and Critical Care Medicine|August 10, 2005
New antibiotics in pulmonary and critical care medicine: focus on advanced generation quinolones and cephalosporinsP G Ambrose, R C Owens
Current Opinion in Microbiology|October 26, 2000
Pharmacodynamics in the study of drug resistance and establishing in vitro susceptibility breakpoints: ready for prime timeM N Dudley, P G Ambrose
Diagnostic Microbiology and Infectious Disease|December 8, 2000
The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs: fluoroquinolone pharmacodynamics against Streptococcus pneumoniaeP G Ambrose, D M Grasela
The American Journal of Medicine|January 5, 2002
Pharmacodynamic profiling of levofloxacin and gatifloxacin using Monte Carlo simulation for community-acquired isolates of Streptococcus pneumoniaeD P Nicolau, P G Ambrose
Infection|July 25, 2009
A long journey from minimum inhibitory concentration testing to clinically predictive breakpoints: deterministic and probabilistic approaches in deriving breakpointsA Dalhoff, P G Ambrose, J W Mouton
The Medical Clinics of North America|January 13, 2001
Antimicrobial pharmacodynamicsP G Ambrose, R C Owens, D Grasela
The Annals of Pharmacotherapy|May 1, 1997
Pharmacoeconomic analysis of administration of famotidine i.v. push vs.intermittent slow i.v. infusionP G Ambrose, R Quintiliani, C H Nightingale
Connecticut Medicine|April 1, 1997
Ceftazidime to cefepime formulary switch: pharmacodynamic and pharmacoeconomic rationaleR C Owens, P G Ambrose, R Quintiliani
Pageof 5